I-Chien Jan

Dr. I-Chien (IC) Jan is the founder & Committee Chair of Taiwan Global Angels (TGA), a global network of seasoned angel investors to leverage Taiwan’s unique strengths in manufacturing, healthcare and talents for growth. Before creating TGA, Dr. Jan was the Chief Strategy Officer at Hukui Bio since January 2021. He was appointed as the Senior Advisor to the Dean at UC Berkeley School of Public Health in August 2021 and also invited to join the Berkeley SkyDeck and 500 Startups Accelerators to share his experiences and to help startup founders on fundraising, team building and go-to-market strategy on a pro bono basis as a Mentor since 2020. Before doing research as a Visiting Scholar at UC Berkeley in 2020, Dr. Jan was the Assistant CEO of BioHub Taiwan since 2018 to strengthen the biomedical startup ecosystem in Taiwan. Concentrated on fields of translational medicine and digital healthcare, Dr. Jan aspires to aid startups in “Get Local and Go Global”. He represents the government to join many international conferences including BIO, BioJapan, and RESI JP Morgan Healthcare. He also conducted the first “Biomedical Startup Challenge” partnering with AstraZeneca Global Innovation Program in Taiwan. Dr. Jan has also been selected as the Startup Ecosystem Ambassador 2019 for Startup Genome, a world-renowned startup research organization, to connect with startup leaders, community builders and key startup support organizations and programs (SSOPs) in Taiwan. Prior to joining BioHub, Dr. Jan was a co-founder and partner of AppWorks Ventures between 2010-2016. As Asia’s leading startup accelerator and most active early-stage VC, AppWorks and its renowned 6-month free program now admit 30 startups per batch across the region. 372 active startups and 1,288 founders make up its alumni network. All AppWorks startups together generate 5.8B USD in annual revenues, provide 15,000 jobs and are valued at 5.3B USD. As a VC, AppWorks has 170M USD under management. It funds 10 deals a year, owns 50 names in its portfolio and has so far produced 4 IPOs. Besides venture business, Dr. Jan proposed and was elected to the "Youth Advisory Group of Executive Yuan" since 2014 to 2016 as an opinion leader and young advisor to the government. He participated in many startup-related policy-making deliberations including the "Defer Taxation of Technical Stocks", "HeadStart Taiwan", "Relaxation of Stock Market Price Limits ", "Close Corporation Law" and other issues. Between 2010 and 2012, Dr. Jan was a VP & Acting CEO at ARDIC Instruments, a technology transformation and commercialization platform offering pipelines of analytical instruments in biotech and nanotech. From 2007 to 2010, Dr. Jan was Director of Development Dept. at Chang-Yu Technology (CYT) and Vice President at OTO Science with a focus on miniature optical spectrometer based on MEMs technology. From 2004 to 2007, Dr. Jan worked for top-tier biotech and IT venture funds including independent VC (ChengXin VC Group), Banking VC (Industrial Bank of Taiwan), and corporate VC (Harbinger Ventures of MiTAC/Synnex Group) in Taiwan. He received a doctoral degree in Biomedical Engineering from National Taiwan University (2004) and an MBA in intellectual Property from National Chengchi University (2009).